VOYAGER THERAPEUTICS INC (VYGR)
US92915B1061 - Common Stock
Taking everything into account, VYGR scores 6 out of 10 in our fundamental rating. VYGR was compared to 587 industry peers in the Biotechnology industry. VYGR is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VYGR has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year VYGR was profitable.
VYGR had a positive operating cash flow in the past year.
In multiple years VYGR reported negative net income over the last 5 years.
In multiple years VYGR reported negative operating cash flow during the last 5 years.
1.2 Ratios
VYGR has a better Return On Assets (37.66%) than 99.83% of its industry peers.
VYGR has a better Return On Equity (55.98%) than 99.49% of its industry peers.
With an excellent Return On Invested Capital value of 33.63%, VYGR belongs to the best of the industry, outperforming 99.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.66% | ||
| ROE | 55.98% | ||
| ROIC | 33.63% |
ROA(3y)-9.39%
ROA(5y)-5.28%
ROE(3y)-32.51%
ROE(5y)-23.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of VYGR (52.91%) is better than 99.83% of its industry peers.
In the last couple of years the Profit Margin of VYGR has grown nicely.
The Operating Margin of VYGR (48.81%) is better than 99.66% of its industry peers.
VYGR's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.81% | ||
| PM (TTM) | 52.91% | ||
| GM | N/A |
OM growth 3Y44.98%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VYGR is creating value.
VYGR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VYGR has more shares outstanding
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.18 indicates that VYGR is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.18, VYGR is in the better half of the industry, outperforming 76.41% of the companies in the same industry.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.18 |
ROIC/WACC3.69
WACC9.11%
2.3 Liquidity
VYGR has a Current Ratio of 4.96. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
VYGR has a Current ratio (4.96) which is in line with its industry peers.
A Quick Ratio of 4.96 indicates that VYGR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.96, VYGR is in line with its industry, outperforming 54.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.96 | ||
| Quick Ratio | 4.96 |
3. Growth
3.1 Past
VYGR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 353.28%, which is quite impressive.
Measured over the past years, VYGR shows a very strong growth in Earnings Per Share. The EPS has been growing by 48.16% on average per year.
VYGR shows a strong growth in Revenue. In the last year, the Revenue has grown by 509.90%.
VYGR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 101.11% yearly.
EPS 1Y (TTM)353.28%
EPS 3Y48.16%
EPS 5YN/A
EPS growth Q2Q304.92%
Revenue 1Y (TTM)509.9%
Revenue growth 3Y13.48%
Revenue growth 5Y101.11%
Revenue growth Q2Q6104.07%
3.2 Future
The Earnings Per Share is expected to decrease by -19.33% on average over the next years. This is quite bad
VYGR is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -22.99% yearly.
EPS Next Y-159.28%
EPS Next 2Y-60.3%
EPS Next 3Y-35.37%
EPS Next 5Y-19.33%
Revenue Next Year-76.67%
Revenue Next 2Y-43%
Revenue Next 3Y-30.69%
Revenue Next 5Y-22.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
VYGR is valuated cheaply with a Price/Earnings ratio of 2.77.
Based on the Price/Earnings ratio, VYGR is valued cheaper than 99.15% of the companies in the same industry.
VYGR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.05.
VYGR is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.77 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VYGR is valued cheaply inside the industry as 99.32% of the companies are valued more expensively.
VYGR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VYGR is cheaper than 99.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.24 | ||
| EV/EBITDA | 0.66 |
4.3 Compensation for Growth
VYGR has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as VYGR's earnings are expected to decrease with -35.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-60.3%
EPS Next 3Y-35.37%
5. Dividend
5.1 Amount
No dividends for VYGR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VOYAGER THERAPEUTICS INC
NASDAQ:VYGR (5/8/2024, 7:00:03 PM)
After market: 8.59 +0.02 (+0.23%)8.57
-0.2 (-2.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap466.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.77 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.66% | ||
| ROE | 55.98% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 48.81% | ||
| PM (TTM) | 52.91% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.96 | ||
| Quick Ratio | 4.96 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)353.28%
EPS 3Y48.16%
EPS 5Y
EPS growth Q2Q
EPS Next Y-159.28%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)509.9%
Revenue growth 3Y13.48%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y